05 June 2017 | News
Cure-One's N1 registry plans to align with the direction and efforts of other national and international groups seeking to advance precision medicine.
Cure-One, a non-profit organization dedicated to advancing precision medicine, announced the participation of Guardant Health, the leader in comprehensive liquid biopsy testing, as a cornerstone laboratory in Cure-One's N1 Registry.
The N1 Registry seeks to better understand the genetic basis of malignancy as it relates to physician decisions and patient outcomes. It also intends to collect granular genomic data to allow a more comprehensive understanding of the complexity, intricacy, and application of advanced genomic sequencing analyses as it relates to clinical outcomes.
N1 registry plans to align with the direction and efforts of other national and international groups seeking to advance precision medicine.
Dane J. Dickson, M.D., Chief Executive Officer and Founder of Cure-One pointed out that Guardant Health is the world leader in liquid biopsies, and its participation with N1 Registry is a testament to its commitment to advance the field of precision medicine, and to increase the availability of non-invasive comprehensive sequencing to advanced cancer patients.
Guardant Health has raised more than $500 million from leading venture capital firms. Its first product, the Guardant360 assay, came to market in 2014, and is now the most widely ordered comprehensive liquid biopsy commercially available. Guardant Health and Guardant360 are registered trademarks of Guardant Health, Inc.